Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of AMG0001 to Improve Perfusion in Critical Leg Ischemia

NCT00060892 is registered in ClinicalTrials.gov with AnGes USA, Inc. as lead sponsor.

NCT NCT00060892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00060892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of AMG0001 to Improve Perfusion in Critical Leg Ischemia
Lead sponsor
AnGes USA, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2003
Completion date
January 31, 2007
Enrollment
104 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

arterial occlusive disease, ischemia, peripheral vascular disease